Currently, advanced NSCLC patients are candidates to first-line therapy with EGFR TKIs such as gefitinib and erlotinib if their tumors bear activating mutations of EGFR that have been recognized as the major determinant of effective tumor response to these targeted agents [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.